Leukemia News

Two teenagers with T-cell acute lymphoblastic leukemia achieved complete molecular remission after receiving a donor-based investigational chimeric antigen receptor T-cell therapy, phase 1 study results showed.

CHICAGO — Healio | HemOnc Today gathered the best, brightest and boldest in oncology for its second annual Disruptive Innovators Awards.

CHICAGO — The addition of venetoclax to ibrutinib and obinutuzumab did not extend PFS among older patients with treatment-naive chronic lymphocytic leukemia during the COVID-19 pandemic, according to data presented at ASCO Annual Meeting.

CHICAGO — Lisocabtagene maraleucel significantly improved complete remission rates among adults with relapsed or refractory chronic lymphocytic leukemia, results from the pivotal phase 2 TRANSCEND CLL 004 trial showed.

INDIANAPOLIS — Compared with siblings, survivors of childhood cancer have an increased risk for sleep concerns up to 30 years after diagnosis, according to a report from the Childhood Cancer Survivor Study.

New prior authorization policies appeared associated with about a 2-week delay in oral oncology drug prescription fills, according to study results presented during ASCO Annual Meeting.

CHICAGO — Ivosidenib extended median OS more than three times longer than placebo when added to azacitidine for adults with treatment-naive, IDH1-mutated acute myeloid leukemia, according to updated results of the phase 3 AGILE trial.

CHICAGO — During ASCO Annual Meeting, Healio honored our Healio Disruptive Innovators in hematology/oncology in our second annual award ceremony.

CHICAGO — Fewer than half of adolescents and young adults with acute lymphoblastic leukemia received first-line treatment at a specialized cancer center, despite an association of such treatment with longer survival, study results showed.

In this edition, cross-border partnership takes on survival gap for children with leukemia; ‘paradigm shift’ in transfusion-dependent myelodysplastic syndrome; FDA approves Ayvakit for mastocytosis and more.